

NOV 30 1999

K993825

510(k) Summary of Safety and Effectiveness

**510(k) Submitter:** Streck Laboratories, Inc.  
P.O. Box 45625  
Omaha, NE 68145-0625

**Official Correspondent:** Paul Kittelson  
Quality Assurance/Regulatory Affairs  
(402) 691-7465

**Date Prepared:** November 8, 1999

**Names of Device:**  
Trade Name: Para Tech Plus Retics  
Common Name: Assayed hematology control  
Classification Name: White and red cell (and reticulocyte) control (§ 864.8625)

**Predicate Device:** Para Tech (K896154) manufactured by Streck Laboratories

**Description:** Para Tech Plus Retics is a suspension of stabilized human red blood cells, human white cells, simulated human platelets, and simulated human reticulocytes packaged in glass vials containing 4.0 mL volumes. Closures are injection molded polypropylene screw-top caps. The vials are packaged in polystyrene jars.

**Intended Use:** Para Tech Plus Retics is intended to be used as a control for complete blood cell count (CBC), white cell five-part differential, and reticulocyte parameters on Bayer Advia 120 and Technicon H-Series hematology instruments.

**Comparison with Predicate Device:** Like Para Tech, Para Tech Plus Retics is intended for CBC/WBC differential performance validation of Bayer Advia 120 and Technicon H-Series hematology instruments. Both devices contain stabilized human red blood cells, human white cells, and simulated platelets which properly mimic human whole blood components on Bayer Advia 120 analyzers.

Unlike Para Tech, Para Tech Plus Retics contains a stabilized human reticulocyte component. This allows the Advia user to control CBC, WBC differential, and on-line reticulocyte analysis simultaneously with a single device.

**Discussion of Tests and Test Results:** Four studies of Para Tech Plus Retics were conducted: I) Run to Run Reproducibility and Comparison to Whole Blood; II) Site to Site Reproducibility; III) Long Term Stability; and IV) Open Vial Stability. Study results showed Para Tech Plus Retics to be consistently reproducible, substantially equivalent to the predicate product, and stable for the entire product dating.

**Conclusions Drawn From Tests:** Para Tech Plus Retics is safe and effective for controlling CBC/Diff/Retic parameters on Bayer Advia 120 and Technicon H-Series instruments when used as instructed in the product package insert.



DEPARTMENT OF HEALTH & HUMAN SERVICES

NOV 30 1999

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

Mr. Paul Kittelson  
Quality Assurance/Regulatory Affairs  
Streck Laboratories, Inc.  
14124 Industrial Road  
Omaha, Nebraska 68144

Re: K993825  
Trade Name: Para Tech Plus Retics  
Regulatory Class: II  
Product Code: JCN  
Dated: November 8, 1999  
Received: November 12, 1999

Dear Mr. Kittelson:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.


Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>"

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive, slightly slanted style.

Steven I. Gutman, M.D., M.B.A.  
Director  
Division of Clinical Laboratory Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

510(k) Number (if known): K 993825  
~~Not Assigned~~

Device Name: Para Tech Plus Retics

**Indications for Use:** Para Tech Plus Retics is intended to be used as a control for complete blood cell count (CBC), white cell five-part differential, and reticulocyte parameters on Bayer Advia 120 and Technicon H-Series hematology instruments.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

*John E. Mackinn*  
(Division Sign-Off)

Division of Clinical Laboratory Devices

510(k) Number

14993825

Prescription Use ☒  
(Per 21CFR 801.109)

OR

Over-The-Counter Use ☐  
(Optional format 1-2-96)

Date October 6, 1999